This biotech powerhouse could maintain its strength for the long term.
Slate Medicines has emerged with hopes of cracking the code for delivering an injectable novel drug class to prevent ...
GSK is continuing to bolster its siRNA portfolio by paying $40 million upfront for a pair of oligonucleotide therapies from China’s Frontier Biotechnologies. | GSK is continuing to bolster its siRNA ...
AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.
Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...
Raleigh-based Slate Medicines just pulled in a hefty $130 million Series A, a war chest the startup says will fuel development of SLTE‑1009, an in‑licensed anti‑PACAP monoclonal antibody aimed at ...
InvestorsHub on MSN
Fortress Biotech to Receive $205M as Cyprium Agrees Sale of Rare Pediatric Disease Priority Review Voucher
Fortress Biotech, Inc. (NASDAQ:FBIO) said its majority-owned subsidiary Cyprium Therapeutics has signed a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for gross ...
Our mission has always been clear: to eliminate contaminated food products from reaching consumers by making food ...
Our fourth annual, two-day international event gathers top executives across commercial real estate and life sciences to dive into biotech growth, facilities of the future, innovative lab development, ...
Celebrate International Day of Women and Girls in Science 2026 by discovering some of the most influential women shaping biotech today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results